Cryder Capital Partners LLP Reduces Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Cryder Capital Partners LLP lowered its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 5.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 569,765 shares of the company’s stock after selling 32,324 shares during the quarter. HCA Healthcare makes up about 12.4% of Cryder Capital Partners LLP’s portfolio, making the stock its 3rd biggest holding. Cryder Capital Partners LLP’s holdings in HCA Healthcare were worth $171,015,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Atomi Financial Group Inc. acquired a new stake in shares of HCA Healthcare during the third quarter worth approximately $233,000. CWM LLC lifted its stake in HCA Healthcare by 4.3% in the third quarter. CWM LLC now owns 10,288 shares of the company’s stock valued at $4,181,000 after acquiring an additional 421 shares during the last quarter. UMB Bank n.a. lifted its stake in HCA Healthcare by 2.4% in the third quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock valued at $529,000 after acquiring an additional 30 shares during the last quarter. Valeo Financial Advisors LLC lifted its stake in shares of HCA Healthcare by 11.5% in the third quarter. Valeo Financial Advisors LLC now owns 1,060 shares of the company’s stock worth $431,000 after buying an additional 109 shares during the last quarter. Finally, Crestmont Private Wealth LLC acquired a new stake in shares of HCA Healthcare in the third quarter worth $240,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HCA has been the subject of a number of analyst reports. TD Cowen reduced their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research note on Monday, October 28th. Barclays dropped their target price on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Royal Bank of Canada dropped their target price on shares of HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a research report on Monday, January 27th. Wells Fargo & Company lowered shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $400.00 to $320.00 in a research report on Monday, November 25th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $380.00 price target on shares of HCA Healthcare in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $385.67.

Insiders Place Their Bets

In other news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now directly owns 52,702 shares in the company, valued at $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Down 0.8 %

Shares of NYSE HCA opened at $321.95 on Monday. The firm has a market capitalization of $81.55 billion, a PE ratio of 14.65, a price-to-earnings-growth ratio of 1.11 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $417.14. The firm’s 50-day moving average is $313.75 and its 200-day moving average is $353.44.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same quarter last year, the business posted $5.90 EPS. Equities analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be issued a dividend of $0.72 per share. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, March 17th. HCA Healthcare’s dividend payout ratio (DPR) is 12.02%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.